Nipah Virus Rapid Test Development: IVD Antibody and Antigen Strategy

Nipah virus (NiV) has caused at least 26 outbreaks since its discovery in Malaysia in 1998, with mortality rates consistently exceeding 40%. Despite its WHO Blueprint priority status, approved diagnostics remain scarce: most confirmed cases still rely on RT-PCR performed in reference laboratories, creating a critical gap in low-resource outbreak settings where rapid field results could prevent hospital-acquired transmission. This article examines the biology, diagnostic targets, and practical considerations for IVD developers working on NiV rapid tests.

1. What Is Nipah Virus? Epidemiology and Outbreak Risk

Nipah virus is an enveloped, negative-sense RNA virus in the genus Henipavirus, family Paramyxoviridae. Its natural reservoir hosts are fruit bats of the genus Pteropus (flying foxes), which shed the virus in urine, saliva, and birthing fluids without showing clinical signs. Human infections occur through:

• Direct contact with infected bat secretions (fruit contaminated with bat urine is the probable route in Malaysia and Bangladesh)
• Contact with infected intermediate hosts (pigs in the 1998–1999 Malaysia outbreak)
• Person-to-person transmission via respiratory secretions and close physical contact (documented in Bangladesh and India since 2001)

Two genetically distinct lineages circulate: NiV-M (Malaysia lineage, fatality ~40%, primarily porcine amplification) and NiV-B (Bangladesh lineage, fatality ~70–75%, person-to-person transmission more common). Any diagnostic assay must demonstrate performance across both lineages.

2. NiV Biology: Antigens Relevant to Diagnostics

NiV has a genome of approximately 18.2 kb encoding six proteins. Three are diagnostically significant:

For practical IVD development, the N protein is the most accessible target: it is highly conserved across NiV lineages, expressed at high levels in infected cells, and secreted into body fluids during acute infection. N protein expressed in E. coli (after refolding) or in insect cells provides sufficient immunogenicity for use as a capture antigen in lateral flow IgG/IgM assays.

3. Diagnostic Approaches: PCR vs Serology vs Antigen RDT

Current NiV diagnostic options each have distinct windows, infrastructure requirements, and performance profiles:

• RT-PCR (gold standard): Detects viral RNA in throat swabs, urine, and CSF. Sensitivity >95% during acute phase (days 1–10). Requires BSL-3 laboratory, cold chain for reagents, and trained personnel. Turnaround 4–24 hours.
• IgM/IgG ELISA: Detects seroconversion, typically from day 5–8 post-symptom onset. High specificity when using NiV-specific antigens. Standard reference serology method. Lab-based, not field-deployable.
• Antigen-detection RDT: Detects NiV N protein directly in respiratory specimens. Potential for results in 15–20 minutes at point of care. Sensitivity depends on viral load and sample type — highest in respiratory secretions during peak viremia.
• IgM/IgG lateral flow RDT: Serology in field-deployable format. Limited by the 5–8 day serology window — may miss early acute cases. Most useful for outbreak investigation and hospital triage.

4. Antibody Selection for NiV Lateral Flow Assays

Developing anti-NiV monoclonal antibodies requires careful attention to:

Epitope Mapping Across Both Lineages

NiV-M and NiV-B N proteins share approximately 92% amino acid identity. Antibodies must be screened against both lineage-specific recombinant N proteins to confirm cross-reactivity. Antibodies recognizing conserved N-terminal or central domain epitopes typically show broader lineage coverage than those targeting the variable C-terminal domain.

Affinity Requirements for Lateral Flow

LFA capture antibodies require a KD in the range of 10⁻¹⁰ to 10⁻¹¹ M to retain sufficient antigen from the relatively dilute NiV-N concentrations expected in field samples. Detection antibodies labeled with colloidal gold should have moderate affinity (KD 10⁻⁹ to 10⁻¹⁰ M) to allow fast kinetics on the nitrocellulose membrane.

Avoiding Interference from Human Ephrin Receptors

NiV G protein binds to human ephrin-B2 and ephrin-B3, which are expressed at low levels on circulating cells. Anti-G antibodies must be confirmed to not bind human ephrin receptors in bridging assays to prevent false-positive capture of host cell-associated material.

5. Cross-Reactivity and Panel Design Considerations

NiV shares the Henipavirus genus with Hendra virus (HeV), and clinically documented human NiV infection must be distinguished from HeV in Australia and neighboring regions. The minimum cross-reactivity panel for regulatory submission should include:

• Hendra virus N protein (HeV shares ~70% identity with NiV-N)
• Cedar virus and Mojiang virus antigens (emerging henipaviruses)
• Common respiratory paramyxoviruses: RSV, PIV-1, PIV-2, PIV-3, mumps
• Measles virus (same family, potential cross-reactive epitopes)

A well-designed NiV rapid test should detect both NiV-M and NiV-B with equivalent sensitivity, cross-react with HeV in a defined and clinically useful range, and show no significant cross-reactivity with common respiratory paramyxoviruses.

6. Field Deployment and Stability Requirements

NiV outbreaks occur in tropical and subtropical regions with challenging environmental conditions. Field-deployed RDTs must meet:

• Thermal stability: Performance maintained at 2–30°C storage (18 months minimum) and operational stability at ambient temperatures up to 40°C for the test duration
• No cold chain requirement: Lyophilized or dried reagents preferred over liquid-based conjugates
• Whole blood compatibility: Fingerstick whole blood avoids centrifugation, critical for rural outbreak settings
• Sample volume: 10–20 µL fingerstick blood (with running buffer) for field usability

Sekbio's ISO 13485-manufactured anti-NiV antibody reagents and recombinant N protein antigens include stability data under accelerated and real-time conditions to support regulatory submissions for tropical-market deployment.

7. Frequently Asked Questions — Nipah Virus Rapid Test Development

What is Nipah virus and why is it a diagnostic priority?

Nipah virus (NiV) is a zoonotic paramyxovirus that causes severe encephalitis and respiratory illness with case fatality rates of 40–75%. Classified as a BSL-4 pathogen and WHO Blueprint priority pathogen, it spreads from fruit bats to humans and has documented person-to-person hospital transmission in Bangladesh and India — making field-deployable rapid diagnostics critical for outbreak containment.

Which NiV proteins are the best targets for rapid test development?

The nucleocapsid (N) protein is the primary target for antigen-detection RDTs: abundantly expressed, highly immunogenic, and detectable in respiratory secretions and urine during acute infection. For serology, glycoprotein (G) and fusion protein (F) are preferred capture antigens for IgG/IgM lateral flow formats, as patient antibodies against these surface proteins appear within 5–8 days and persist long term.

How do you address cross-reactivity with Hendra virus in a NiV rapid test?

NiV and Hendra virus share approximately 70% nucleotide identity in the N protein, and patient antibodies cross-react. For pan-henipavirus surveillance this is acceptable. For NiV-specific typing, antibodies targeting the hypervariable C-terminal domain of N protein (which has lower HeV homology) can provide discrimination. Minimum cross-reactivity panels should include HeV N protein, Cedar virus, and common respiratory paramyxoviruses.

What sample type is recommended for NiV rapid antigen detection?

Nasopharyngeal swabs in viral transport medium and urine are the highest-yield sample types for NiV antigen detection during acute illness. Blood has lower antigen concentrations due to rapid immune clearance. For IgG/IgM serology tests, fingerstick whole blood or serum is appropriate — the same sample types used for other viral serology RDTs.

What sensitivity and specificity benchmarks should a NiV rapid test achieve?

WHO Emergency Use Listing criteria require sensitivity ≥90% and specificity ≥97% versus validated reference methods (RT-PCR for antigen; PRNT for serology). Given NiV's high fatality rate, false negatives carry more clinical risk than false positives. Clinical evaluation should be powered to demonstrate ≥90% sensitivity with a 95% CI lower bound above 80%.

Can Sekbio supply recombinant NiV antigens and antibody pairs for rapid test development?

Yes. Sekbio develops recombinant NiV nucleocapsid protein and anti-NiV monoclonal antibody pairs for lateral flow and ELISA development, produced under ISO 13485 with documented cross-reactivity and lot consistency data. Visit our Antibody Development Services page to discuss your NiV diagnostic project requirements.

8. Summary

• NiV is a BSL-4 pathogen with high mortality and hospital transmission risk — rapid, field-deployable diagnostics are a public health priority.
• The N protein is the best antigen target for both antigen-detection RDTs and IgM/IgG serology capture, accessible as recombinant protein from E. coli or baculovirus expression.
• Dual-platform strategy: antigen RDT for early acute detection + IgM/IgG LFA for outbreak contact tracing, mirrors dengue's successful NS1 + antibody approach.
• Cross-reactivity with Hendra virus must be characterized — acceptable for henipavirus surveillance, requiring C-terminal domain antibodies for NiV-specific typing.
• Field deployment requires thermal stability to 40°C, whole blood compatibility, and no cold chain — all critical design parameters for tropical outbreak use.

Sekbio's monoclonal antibody pairs for emerging infectious diseases include anti-NiV reagents manufactured under ISO 13485, with stability and cross-reactivity data to support regulatory submissions in WHO priority pathogen programs.